华东医药：2023年半年度报告（英文版）.PDF

1、2023 Semi-Annual Report of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.Semi-Annual Report 2023 August 16,2023 2023 Semi-Annual Report of Huadong Medicine Co.,Ltd.2 Section I.Important Declaration,Contents and Definitions The Board of Directors,Board of Supervisors,directors,supervisors and s

2、enior managers of Huadong Medicine Co.,Ltd.(hereinafter referred to as the“Company”)hereby guarantee that the information presented in this semi-annual report is authentic,accurate and complete and free of any false records,misleading statements or material omissions,and shall undertake individual a

3、nd joint legal liabilities.Lv Liang,the Companys legal representative and the officer in charge of accounting,and Qiu Renbo,head of the Accounting Department(accounting supervisor)hereby declare and guarantee that the financial statements in this semi-annual report are authentic,accurate and complet

4、e.All directors have attended the board meeting to review this semi-annual report.The future plans,development strategies and other forward-looking statements in this semi-annual report shall not be considered as substantial commitment of the Company to investors.Investors and related parties should

5、 be fully aware of the risks,and understand the differences between plans,forecasts and commitments.The risks the Company faces in operation include industry policy and product price reduction risk,new drug R&D risk,investment and M&A risk,and exchange rate fluctuation risk.For details,please refer

6、to“X.Potential risks and responses”in“Section III.Management Discussion and Analysis”.Therefore,investors are kindly reminded to pay attention to possible 2023 Semi-Annual Report of Huadong Medicine Co.,Ltd.3 investment risks.The Company does not plan to distribute cash dividends,no bonus share will